Exhibit 99.1

FOR IMMEDIATE RELEASE

Company Contact:	Investor Relations Contacts:	Media Contact:
AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com	EVC Group, Inc. Doug Sherk / Jenifer Kirtland (415) 896-6820 dsherk@evcgroup.com jkirtland@evcgroup.com	EVC Group, Inc. Chris Gale (646) 201-5431 cgale@evcgroup.com

AngioDynamics Reports Strong Finish to Fiscal 2010

·   Fourth Quarter Net Sales Increase 14% to $60.3 Million

·   First $1.0 Million NanoKnife® IRE System Net Sales Quarter

·   Record $16.1 Million Operating Cash Flow Quarter

·   Fourth Quarter Net Income Grows 29%

·   Company Provides Guidance for FY 2011

·   Conference Call Begins Today at 4:30 p.m. Eastern Time

ALBANY, NY (July 15, 2010) — AngioDynamics (NASDAQ: ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today reported financial results for the fiscal fourth quarter and year ended May 31, 2010.

Net sales in the fourth quarter were $60.3 million, a 14% increase over the $52.8 million reported for the fourth quarter last year.  Gross margin was 58.0% compared with 61.9% a year ago, with the decline primarily attributable to lower selling prices for certain Peripheral Vascular and Access products in a competitive pricing environment, higher material costs for certain products, and product mix.  Operating income was $6.4 million in the quarter compared with $4.8 million a year ago, which included $702,000 in certain non-recurring costs.  Operating income grew 17% excluding non-recurring items.  Net income was $3.7 million, or $0.15 per share, compared with the prior year’s $2.9 million, or $0.12 per share, and $3.4 million, or $0.14 per share excluding non-recurring items.

Oncology/Surgery sales grew 35% to $16.8 million from the fourth quarter a year ago and included $1.0 million in NanoKnife IRE System sales.  Fiscal 2010 NanoKnife IRE System sales totaled $2.5 million.  Peripheral Vascular sales increased by 13% from the fourth quarter a year ago to $25.5 million.  Access sales were $18.0 million in the quarter, an increase of 1% from a year ago.

AngioDynamics generated cash flow from operations of $16.1 million in the fourth quarter and $40.0 million in the fiscal year.  The Company ended fiscal 2010 with $100.1 million in cash and investments, and $6.8 million in long-term debt.

For the fiscal year, net sales were $216.0 million, an 11% increase over the $195.1 million reported in fiscal 2009; gross margin was 58.8% compared with 61.6% for the prior year; operating income was $20.9 million compared with $16.1 million for the prior year, which included $3.7 million in certain non-recurring costs; and net income was $12.3 million, or $0.50 per share, compared with the prior year’s $9.9 million, or $0.41 per share, and $12.4 million, or $0.51 per share, excluding non-recurring items.

“There is much to like about our fourth quarter,” said Jan Keltjens, President and CEO. “With the significant increase in Oncology/Surgery sales, rising NanoKnife IRE System sales and growing demand for our Varicose Vein products, we achieved our highest level of organic sales growth in eight quarters and ended our fiscal year in a very strong position.  We met the challenge of the difficult pricing environment that continues to pressure our gross margin with tight operating expense control and excellent balance sheet management.  As a result, we delivered strong operating profit growth and record operating cash flow.

“We launched 11 new products in fiscal 2010 and we enter fiscal 2011 with several recently-introduced products that we believe will increase sales growth in our Access products,” continued Mr. Keltjens.  “While we expect the pricing environment to remain challenging, due to our focus on high growth markets, innovation and operating leverage, AngioDynamics is well positioned for profitable growth in the years ahead.”

Highlights of the quarter, and more recent activities, include the following:

·   Continued strong clinical interest in AngioDynamics’ NanoKnife IRE System resulted in the treatment of an additional 76 patients since March 31 2010. The number of patients treated to date with the NanoKnife system now totals 230.  Procedures have been performed in many organs, including prostate, liver, lung, and pancreas.

·   Four hospitals entered into a commercial agreement for the NanoKnife IRE System during the fourth quarter, including the first center outside the U.S.

·   The first patient treatment was completed in the pilot study of the use of the Company’s NanoKnife IRE System in the treatment of early stage hepatocellular carcinoma (HCC), or primary liver cancer.  This clinical trial is being conducted under the supervision of Dr. Jordi Bruix of the Barcelona Liver Cancer Group of the University of Barcelona and Dr. Riccardo Lencioni of the University of Pisa School of Medicine.  Updates on the status of the study, titled “A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC),” can be found at www.clinicaltrials.gov.

·   An article, “Irreversible Electroporation: A New Challenge in ‘Out of Operating Theater’ Anesthesia,” authored by Christine Ball, MBBS; Kenneth R. Thomson, MD; and Helen Kavnoudias, PhD, was published in Anesthesia & Analgesia, May 2010, Volume 110, Number 5.

·   The new Morpheus® Smart PICC Triple Lumen CT PICC was introduced.  The product features Smart Taper™ technology, allowing the catheter to quickly taper from a seven French diameter to a precise six French diameter, improving blood flow and reducing the risk of thrombosis.

·   The Company expanded its Smart Port CT family of power-injectable ports, featuring its patented Vortex® port technology, to include low-profile and mini models for repeated treatments such as chemotherapy and for use with computed tomography (CT). The new models offer additional placement options for specialized anatomies, such as smaller patients.

Fiscal 2011 Guidance

The Company’s outlook for fiscal 2011 is as follows:

·   Net sales in the range of $230 million to $235 million, an increase of 6% to 9% over fiscal 2010 net sales  

·   Gross margin in the range of 58% to 59% of net sales  

·   GAAP operating income in the range of $22.5 million to $23.5 million, an increase of 8% to 13%  

·   EBITDA in the range of $35 million to $36 million  

·   GAAP EPS in the range of $0.53 to $0.56, an increase of 6% to 12%, inclusive of a $0.23 EPS impact from the IRE program

Conference Call

AngioDynamics management will host a conference call to discuss its fiscal fourth quarter results today beginning at 4:30 p.m. Eastern Time. To participate in the live call by telephone, please dial 1 (877) 941-2332.

In addition, individuals can listen to the call on the Internet by visiting the investor relations portion of the AngioDynamics Web site at http://investors.angiodynamics.com. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download and install the necessary audio software.  In addition, a replay of the call will be available at http://investors.angiodynamics.com.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported non-GAAP EBITDA (income before interest, taxes, depreciation and amortization). Management uses this measure in its internal analysis and review of operational performance. Management believes that this measure provides investors with useful information in comparing AngioDynamics’ performance over different periods. By using this non-GAAP measure, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of Operating Income to non-GAAP measures.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease.  AngioDynamics’ diverse product lines include market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

		Three months ended						Twelve months ended
		May 31,			May 31,			May 31,			May 31,
		2010			2009			2010			2009
		(unaudited)						(unaudited)				(2)
Net sales		$	60,277		$	52,820		$	216,035		$	195,054
Cost of sales			25,320			20,127			89,066			74,989
	Gross profit		34,957			32,693			126,969			120,065
	% of net sales		58.0	%		61.9	%		58.8	%		61.6	%
Operating expenses
Research and development			5,374			4,835			19,275			17,914
Sales and marketing			16,491			16,281			60,923			57,797
General and administrative			4,254			3,803			16,437			15,381
Non-recurring costs			-			702			-			3,743
Amortization of intangibles			2,456			2,310			9,463			9,126
	Total operating expenses		28,575			27,931			106,098			103,961
	Operating income		6,382			4,762			20,871			16,104
Other income (expense), net			(563	)		(294	)		(1,252	)		(952	)
	Income before income taxes		5,819			4,468			19,619			15,152
Provision for income taxes			2,081			1,566			7,307			5,220
	Net income	$	3,738		$	2,902		$	12,312		$	9,932
Earnings per common share
	Basic	$	0.15		$	0.12		$	0.50		$	0.41
	Diluted	$	0.15		$	0.12		$	0.50		$	0.41
Weighted average common shares
	Basic		24,743			24,427			24,580			24,363
	Diluted		24,969			24,544			24,787			24,513
(2)	Derived from audited financial statements

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

Reconciliation of Operating Income to non-GAAP EBITDA:
		Three months ended				Twelve months ended
		May 31,		May 31,		May 31,		May 31,
		2010		2009		2010		2009
		(unaudited)				(unaudited)
Operating income		$	6,382	$	4,762	$	20,871	$	16,104
Amortization of intangibles			2,456		2,310		9,463		9,126
Depreciation			747		689		2,996		2,687
	EBITDA	$	9,585	$	7,761	$	33,330	$	27,917
EBITDA per common share
	Basic	$	0.39	$	0.32	$	1.36	$	1.15
	Diluted	$	0.38	$	0.32	$	1.34	$	1.14
Weighted average common shares
	Basic		24,743		24,427		24,580		24,363
	Diluted		24,969		24,544		24,787		24,513

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY BUSINESS UNIT AND BY GEOGRAPHY

(in thousands)

		Three months ended				Twelve months ended
		May 31,		May 31,		May 31,		May 31,
		2010		2009		2010		2009
		(unaudited)				(unaudited)			(2)
Net Sales by Business Unit
	Peripheral Vascular	$	25,524	$	22,510	$	92,163	$	83,457
	Access		17,994		17,881		66,988		66,812
	Oncology/Surgery		16,759		12,429		56,884		44,785
	Total	$	60,277	$	52,820	$	216,035	$	195,054
Net Sales by Geography
	United States	$	54,152	$	47,144	$	192,933	$	173,406
	International		6,125		5,676		23,102		21,648
	Total	$	60,277	$	52,820	$	216,035	$	195,054
(2)	Derived from audited financial statements

ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
		May 31,		May 31,
		2010		2009
		(unaudited)		(2)
Assets
Current Assets
	Cash and cash equivalents	$	58,763	$	27,909
	Marketable securities		41,311		40,278
	Total cash and investments		100,074		68,187
	Receivables, net		29,838		27,181
	Inventories, net		29,216		36,928
	Deferred income taxes		5,281		9,337
	Prepaid income taxes		5,525		3,694
	Prepaid expenses and other		1,426		3,271
	Total current assets		171,360		148,598
Property, plant and equipment, net			24,193		22,183
Intangible assets, net			58,352		67,770
Goodwill			161,974		161,974
Deferred income taxes			2,527		4,263
Other non-current assets			5,519		3,915
	Total Assets	$	423,925	$	408,703
Liabilities and Stockholders' Equity
Current portion of long-term debt		$	260	$	265
Contractual payments on acquisition of business, net			-		5,227
Other current liabilities			25,766		24,207
Long-term debt, net of current portion			6,550		6,810
	Total Liabilities		32,576		36,509
Stockholders' equity			391,349		372,194
	Total Liabilities and Stockholders' Equity	$	423,925	$	408,703
Shares outstanding			24,747		24,428
(2)	Derived from audited financial statements

ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
				Twelve months ended
				May 31,			May 31,
				2010			2009
				(unaudited)			(2)
Cash flows from operating activities:
	Net income			$	12,312		$	9,932
	Depreciation and amortization				12,459			11,813
	Tax effect of exercise of stock options				(529	)		(149	)
	Deferred income taxes				5,877			4,267
	Stock-based compensation				4,876			5,793
	Other				(940	)		1,611
	Changes in operating assets and liabilities
		Receivables			(2,613	)		351
		Inventories			8,302			(10,532	)
		Accounts payable and accrued liabilities			1,522			5,566
		Litigation provision			-			(6,757	)
		Other			(1,307	)		(1,953	)
			Net cash provided by operating activities		39,959			19,942
Cash flows from investing activities:
	Additions to property, plant and equipment				(5,042	)		(4,361	)
	Acquisition of intangible assets and businesses				(5,411	)		(17,078	)
	Change in restricted cash				-			68
	Purchases, sales and maturities of marketable securities, net				(1,324	)		5,672
			Net cash provided by (used in) investing activities		(11,777	)		(15,699	)
Cash flows from financing activities:
	Repayment of long-term debt				(265	)		(10,040	)
	Proceeds from exercise of stock options and ESPP				2,983			1,774
			Net cash provided by (used in) financing activities		2,718			(8,266	)
			Effect of exchange rate changes on cash		(46	)		(108	)
			Increase (Decrease) in cash and cash equivalents		30,854			(4,131	)
Cash and cash equivalents
			Beginning of period		27,909			32,040
			End of period	$	58,763		$	27,909
(2)	Derived from audited financial statements